PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Pronged attack on Fast-Growing lymphomas enters patient testing
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug, epcoritamab, to a standard chemotherapy regimen (called EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
First human trial tests promising pill for tough blood cancers
Disease control Recruiting nowThis early-stage study is testing a new oral medication called SGR-1505 in adults with advanced B-cell cancers that have returned or stopped responding to previous treatments. The main goal is to find the highest safe dose and understand how the drug affects the body. Researchers…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test powerful new drug cocktail in fight against Fast-Growing lymphoma
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, aggressive B-cell lymphoma. The goal is to see if the new combinations are safe and tolerable for patients. Researchers will enroll a…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug could make revolutionary cancer treatment safer
Disease control Recruiting nowThis study is testing whether a drug called emapalumab can prevent severe side effects that sometimes occur with CAR-T cell therapy, a powerful treatment for certain lymphomas. Researchers will give emapalumab to 28 adults with hard-to-treat lymphoma who are receiving CAR-T thera…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Fighting cancer with re-engineered immune cells: early trial seeks to tame tough lymphomas
Disease control Recruiting nowThis is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two powerful cancer treatments—CAR-T cell therapy and the drug pembrolizumab—works better than either alone for a type of lymphoma that has returned or not responded to prior treatments. About 35 adults with relapsed or refractory primary m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Cancer treatment may wipe out vaccine immunity, study investigates
Knowledge-focused Recruiting nowThis study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Mar 02, 2026 15:28 UTC